Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: A prognostic entity

Cancer Letters

Volumn 264, Issue 2, 2008, Pages 274-280

  Ellinger, Jörg ^a   Bastian, Patrick J ^a   Ellinger, Nadja ^a   Kahl, Philip ^a   Perabo, Frank G ^a   Büttner, Reinhard ^a   Müller, Stefan C ^a   Ruecker, Alexander von ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Bladder cancer; Cell free DNA; Serum

Indexed keywords

DNA FRAGMENT;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER INVASION; CLINICAL ARTICLE; CYSTECTOMY; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE HYPERTROPHY; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; DNA; DNA FRAGMENTATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC HYPERPLASIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; SERUM; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 42749093364     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.01.038     Document Type: Article

References (25)

1. Leon S.A., Shapiro B., Sklaroff D.M., and Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37 (1977) 646-650
2. Chang H.W., Lee S.M., Goodman S.N., Singer G., Cho S.K., Sokoll L.J., Montz F.J., Roden R., Zhang Z., Chan D.W., Kurman R.J., and Shih I. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J. Natl. Cancer Inst. 94 (2002) 1697-1703
3. Umetani N., Giuliano A.E., Hiramatsu S.H., Amersi F., Nakagawa T., Martino S., and Hoon D.S. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J. Clin. Oncol. 24 (2006) 4270-4276
4. Ellinger J., Bastian P.J., Haan K.I., Heukamp L.C., Buettner R., Fimmers R., Mueller S.C., and von Ruecker A. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int. J. Cancer 122 (2008) 138-143
5. Jiang W.W., Zahurak M., Goldenberg D., Milman Y., Park H.L., Westra W.H., Koch W., Sidransky D., and Califano J. Increased plasma DNA integrity index in head and neck cancer patients. Int. J. Cancer 119 (2006) 2673-2676
6. Wu T.L., Zhang D., Chia J.H., Tsao K.H., Sun C.F., and Wu J.T. Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin. Chim. Acta 321 (2002) 77-87
7. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., and Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61 (2001) 1659-1665
8. Zhong X.Y., Hahn S., Kiefer V., and Holzgreve W. Is the quantity of circulatory cell-free DNA in human plasma and serum samples associated with gender, age and frequency of blood donations?. Ann. Hematol. 86 (2007) 139-143
9. Umetani N., Kim J., Hiramatsu S., Reber H.A., Hines O.J., Bilchik A.J., and Hoon D.S. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin. Chem. 52 (2006) 1062-1069
10. Bastian P.J., Palapattu G.S., Yegnasubramanian S., Lin X., Rogers C.G., Mangold L.A., Trock B., Eisenberger M., Partin A.W., and Nelson W.G. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin. Cancer Res. 13 (2007) 5361-5367
11. Gautschi O., Bigosch C., Huegli B., Jermann M., Marx A., Chasse E., Ratschiller D., Weder W., Joerger M., Betticher D.C., Stahel R.A., and Ziegler A. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J. Clin. Oncol. 22 (2004) 4157-4164
12. Chun F.K., Muller I., Lange I., Friedrich M.G., Erbersdobler A., Karakiewicz P.I., Graefen M., Pantel K., Huland H., and Schwarzenbach H. Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int. 98 (2006) 544-548
13. Chan K.C., and Lo Y.M. Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers. Br. J. Cancer 96 (2007) 681-685
14. Wang B.G., Huang H.Y., Chen Y.C., Bristow R.E., Kassauei K., Cheng C.C., Roden R., Sokoll L.J., Chan D.W., and Shih I. Increased plasma DNA integrity in cancer patients. Cancer Res. 63 (2003) 3966-3968
15. Ellinger J., El Kassem N., Heukamp L.C., Mathews S., Cubukluoz F., Kahl P., Perabo F.G., Muller S.C., von Ruecker A., and Bastian P.J. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J. Urol. 179 1 (2008) 346-352
16. Bastian P.J., Palapattu G.S., Lin X., Yegnasubramanian S., Mangold L.A., Trock B., Eisenberger M.A., Partin A.W., and Nelson W.G. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin. Cancer Res. 11 (2005) 4037-4043
17. Dominguez G., Carballido J., Silva J., Silva J.M., Garcia J.M., Menendez J., Provencio M., Espana P., and Bonilla F. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin. Cancer Res. 8 (2002) 980-985
18. Perabo F.G., Kamp S., Schmidt D., Lindner H., Steiner G., Mattes R.H., Wirger A., Pegelow K., Albers P., Kohn E.C., von Ruecker A., and Mueller S.C. Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. Br. J. Cancer 84 (2001) 1330-1338
19. Lee S.H., Lee J.Y., Park W.S., Kim S.Y., Jang J.J., and Yoo N.J. Transitional cell carcinoma expresses high levels of Fas ligand in vivo. BJU Int. 83 (1999) 698-702
20. Chopin D., Barei-Moniri R., Maille P., Frere-Belda M.A., Muscatelli-Groux B., Merendino N., Lecerf L., Stoppacciaro A., and Velotti F. Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am. J. Pathol. 162 (2003) 1139-1149
21. Mizutani Y., Hongo F., Sato N., Ogawa O., Yoshida O., and Miki T. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer 92 (2001) 287-293
22. Thalmann G.N., Markwalder R., Shahin O., Burkhard F.C., Hochreiter W.W., and Studer U.E. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?. J. Urol. 172 (2004) 70-75
23. Denzinger S., Fritsche H.M., Otto W., Blana A., Wieland W.F., and Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?. Eur. Urol. 53 (2008) 146-152
24. Umetani N., Hiramatsu S., and Hoon D.S. Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. Ann. NY Acad. Sci. 1075 (2006) 299-307
25. de Kok J.B., Hendriks J.C., van Solinge W.W., Willems H.L., Mensink E.J., and Swinkels D.W. Use of real-time quantitative PCR to compare DNA isolation methods. Clin. Chem. 44 (1998) 2201-2204